产品
编 号：F353063
分子式：C26H32O11
分子量：520.53
分子式：C26H32O11
分子量：520.53
产品类型
规格
价格
是否有货
结构图
CAS No: 41607-20-9
产品详情
生物活性：
(-)-Pinoresinol 4-O-glucoside ((-)-Pinoresinol 4-O-β-D-glucopyranoside) is a potent and orally active α-glucosidase inhibitor with an IC50 value of 48.13 μM. (-)-Pinoresinol 4-O-glucoside increases cell migration and early differentiation of pre-osteoblasts. (-)-Pinoresinol 4-O-glucoside increases protein level of BMP2, p-Smad1/5/8, RUNX2. (-)-Pinoresinol 4-O-glucoside attenuates oxidative stress, hyperglycemia and hepatic toxicity. (-)-Pinoresinol 4-O-glucoside has the potential for the research of osteoporosis and periodontal disease.
体内研究：
(-)-Pinoresinol 4-O-glucoside (50 mg/kg；口服；20 天) 减轻小鼠的氧化应激、高血糖和肝毒性。Animal Model:27-30 g, Male Swiss albino mice
Dosage:50 mg/kg
Administration:P.o.; twenty days
Result:Exhibited a hepatoprotective activity in vivo as it lowered AST and ALT levels, caused a prominent decline in serum glucose level by 37.83% in streptozotocin-treated mice with promising elevation in insulin level of 25.37%.
体外研究：
(-)-Pinoresinol 4-O-glucoside (0、10、30 μM；24 小时) 在含有 50 μg/mL 的成骨补充培养基 (OS) 中增加前成骨细胞分化过程中的细胞迁移.(-)-Pinoresinol 4-O-glucoside (10、30 μM；7 天) 在前成骨细胞分化过程中增加早期分化并增加矿化结节的形成。(-)-Pinoresinol 4-O-glucoside (10、30 μM；3 天) 增加前成骨细胞中 BMP2、ALP、OCN mRNA 水平的表达。(-)-Pinoresinol 4-O-glucoside (10、30 μM；3 天) 增加 BMP2、p-Smad1/5/8、RUNX2 的蛋白表达水平。
(-)-Pinoresinol 4-O-glucoside ((-)-Pinoresinol 4-O-β-D-glucopyranoside) is a potent and orally active α-glucosidase inhibitor with an IC50 value of 48.13 μM. (-)-Pinoresinol 4-O-glucoside increases cell migration and early differentiation of pre-osteoblasts. (-)-Pinoresinol 4-O-glucoside increases protein level of BMP2, p-Smad1/5/8, RUNX2. (-)-Pinoresinol 4-O-glucoside attenuates oxidative stress, hyperglycemia and hepatic toxicity. (-)-Pinoresinol 4-O-glucoside has the potential for the research of osteoporosis and periodontal disease.
体内研究：
(-)-Pinoresinol 4-O-glucoside (50 mg/kg；口服；20 天) 减轻小鼠的氧化应激、高血糖和肝毒性。Animal Model:27-30 g, Male Swiss albino mice
Dosage:50 mg/kg
Administration:P.o.; twenty days
Result:Exhibited a hepatoprotective activity in vivo as it lowered AST and ALT levels, caused a prominent decline in serum glucose level by 37.83% in streptozotocin-treated mice with promising elevation in insulin level of 25.37%.
体外研究：
(-)-Pinoresinol 4-O-glucoside (0、10、30 μM；24 小时) 在含有 50 μg/mL 的成骨补充培养基 (OS) 中增加前成骨细胞分化过程中的细胞迁移.(-)-Pinoresinol 4-O-glucoside (10、30 μM；7 天) 在前成骨细胞分化过程中增加早期分化并增加矿化结节的形成。(-)-Pinoresinol 4-O-glucoside (10、30 μM；3 天) 增加前成骨细胞中 BMP2、ALP、OCN mRNA 水平的表达。(-)-Pinoresinol 4-O-glucoside (10、30 μM；3 天) 增加 BMP2、p-Smad1/5/8、RUNX2 的蛋白表达水平。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备